The traditional pathway for bringing a new drug to market is notoriously broken. Known in the biotech industry as the “Valley of Death,” the phase between basic laboratory discovery and early-stage clinical trials is where over 90% of promising therapeutic compounds go to die.

For longevity science (LongBio), this valley is even wider and deeper. Because regulatory bodies like the FDA do not currently classify aging as a disease, traditional pharmaceutical giants and venture capital firms rarely fund early-stage preventative treatments (geroprotectors). They prefer late-stage, single-disease interventions that promise immediate, predictable returns.

Enter Decentralized Science (DeSci). By leveraging blockchain technology, intellectual property tokenization, and global web3 communities, DeSci is bypassing traditional institutional bottlenecks. This movement is democratizing how scientific research is funded, conducted, and owned.

The Core Bottleneck: Why Longevity Research Starves

To understand why DeSci is gaining rapid traction, we must look at the structural failures of traditional scientific funding:

1. The Grant Cycle Trap: Academic researchers spend up to 40% of their time writing grant applications instead of doing science. These grants are typically awarded by centralized committees that favor safe, incremental studies over high-risk, high-reward breakthroughs.
2. Intellectual Property Silos: Patents are locked inside university Technology Transfer Offices (TTOs). Negotiating the rights to a compound can take years, stalling potential clinical trials.
3. Lack of Public Alignment: The public—the ultimate consumers of these therapies—has zero say in which diseases are prioritized and no financial upside if a drug succeeds.

DeSci rewrites this playbook by replacing centralized gatekeepers with decentralized autonomous organizations (DAOs) and liquid IP markets.

The DeSci Toolkit: IP-NFTs and IPTs

At the heart of the DeSci revolution is a novel financial and legal primitive: the IP-NFT (Intellectual Property Non-Fungible Token), pioneered by the web3 protocol Molecule .

An IP-NFT is a digital wrapper around a real-world legal agreement. It links a blockchain token directly to intellectual property rights, pre-patent data, or research agreements (such as Sponsored Research Agreements, or SRAs) held by a university or lab.

How the IP-NFT Pipeline Works:

• Step 1: The Proposal. A researcher submits a project proposal to a DeSci platform.
• Step 2: Tokenization. The research project’s future IP and data rights are minted as an IP-NFT on-chain.
• Step 3: Funding. A DAO or a group of web3 investors purchases the IP-NFT, instantly transferring capital to the lab.
• Step 4: Fractionation (IPTs). The IP-NFT can be fractionated into fungible IP Tokens (IPTs). This allows a broader community of patients, researchers, and enthusiasts to own governance rights over the IP, vote on how the data is utilized, and share in future licensing revenues.

This model completely bypasses the bureaucratic friction of university TTOs, turning illiquid scientific assets into liquid, tradeable, and collaborative digital primitives.

VitaDAO: A Case Study in On-Chain Longevity Funding

VitaDAO is the world’s premier DeSci community dedicated to funding early-stage longevity research. Governed by holders of the $VITA token, the DAO has established a highly efficient, community-driven pipeline for evaluating and funding scientific hypotheses.

As of mid-2026, VitaDAO’s real-world impact is undeniable:

• 31+ Projects Funded across target discovery, drug discovery, and preclinical development.
• $4.7M+ in Funding Deployed directly to laboratories globally.
• 8 IP-NFTs (IPTs) Generated, creating a diversified portfolio of longevity assets.
• 3 Biotech Companies Founded based on DAO-funded research.

Real-World Projects Funded by VitaDAO:

• ARTAN Bio ($91,300): Developing mutation-specific codon suppression therapies to combat genetic and age-related diseases caused by premature stop codons.
• Rubedo Life Sciences ($350,000): A prodrug discovery platform targeting senescent cells (zombie cells that drive chronic inflammation and tissue degradation).
• Korolchuk Lab ($285,000): Researching novel autophagy activators to help cells clear out molecular waste, a key hallmark of aging.

AI-Driven Science Acceleration

To scale their operations, VitaDAO has integrated advanced AI agents into their workflow. LAIA (Longevist AI) automatically curates longevity preprints daily, generates research hypotheses, and assists in evaluating incoming project proposals. Meanwhile, AubrAI (an AI specialist trained on the work of longevity pioneer Aubrey de Grey) provides the community with instant, expert-level answers to complex biomedical questions.

How You Can Participate: A Practical Guide

For the first time in history, ordinary individuals do not have to wait for pharmaceutical conglomerates to develop life-extending therapies. You can actively fund, govern, and benefit from the frontier of LongBio.

Step 1: Set Up a Secure Web3 Wallet

To interact with DeSci protocols, you need a secure, non-custodial wallet.

• For maximum security, use a hardware wallet like Trezor , Tangem , or Keystone .
• For daily interactions and multi-signature security, set up a smart contract wallet using Safe or Argent .

Step 2: Join a DeSci DAO

Acquire governance tokens (such as $VITA) to participate in the DAO’s decision-making process. Token holders can vote on which research proposals receive funding, review scientific data, and help steer the direction of the organization.

Step 3: Invest in IP Tokens (IPTs)

Through platforms like Molecule Labs, you can purchase fractionated IP tokens of specific research projects. If a molecule you funded successfully passes clinical trials or is licensed by a major pharmaceutical company, the value of your IPTs reflects that success.

Step 4: Track Your Own Longevity Biomarkers

As you support the development of new molecules, you can monitor your own biological age using advanced epigenetic testing kits from TruDiagnostic (which utilizes the highly accurate DunedinPACE algorithm) or Elysium Health .

Risks, Challenges, and the Road Ahead

While DeSci offers an incredibly promising alternative to traditional biotech funding, it is not without significant hurdles:

• Regulatory Uncertainty: The intersection of securities laws and decentralized governance is highly complex. Molecule’s recent legal frameworks—such as the “Coin-to-Company” model published in March 2026—attempt to solve this by creating compliant pathways to transition decentralized communities into traditional equity structures under U.S. law. However, regulatory scrutiny remains high.
• Scientific Risk: Drug development is inherently risky. A compound that looks miraculous in a petri dish or in mice has a high probability of failing in human clinical trials. DeSci investors must be prepared for the reality that many funded projects will yield negative results.
• Liquidity and Valuation: Valuing early-stage, pre-patent scientific data is incredibly difficult. The market for IPTs is still highly illiquid compared to mainstream crypto assets.

The Verdict: A New Paradigm for Human Healthspan

DeSci is more than just a novel fundraising mechanism; it is a fundamental realignment of incentives. By connecting passionate global communities directly with cutting-edge researchers, protocols like Molecule and DAOs like VitaDAO are dismantling the ivory towers of academia and the closed doors of big pharma.

In a world where aging is the leading cause of disease and suffering, accelerating the translation of basic science into clinical trials is not just a financial opportunity—it is a moral imperative. Through DeSci, the crowd now has the power to fund the cure.

If you start choosing a wearable for sleep and recovery, one awkward truth appears fast: the metrics look similar, but life with each device is different. One needs a subscription, another is annoying at night, a third is excellent for training but turns sleep into another chart without an obvious decision.

As of May 23, 2026, the best way to choose between Oura Ring , WHOOP , Garmin and Ultrahuman is not to start with who is more accurate. Start with what you will actually wear every day. For sleep and HRV, consistency beats a one-off accuracy claim: a tracker sitting on a charger, or irritating your wrist in bed, has already lost.

Quick choice

If you want the calmest sleep tracker in a ring format, look at Oura. It is the strongest ecosystem here for sleep, readiness, stress, women’s health and long-term trends, but it is built around membership: without Oura Membership, the app experience is meaningfully limited.

If you train regularly and want recovery tied to load, habits and coaching, WHOOP is the more natural fit. Its strengths are a screenless design, long battery life and a tight focus on Recovery, Strain and Sleep. The tradeoff is that you are not really buying a gadget. You are joining an annual membership.

If sport matters more than a polished wellness dashboard, choose Garmin. For running, cycling, strength work, hiking, GPS, heart rate zones, training readiness and activity export, Garmin watches are more practical than rings. The catch: you have to sleep with a watch, and comfort depends heavily on the model and size.

If you want a ring without a mandatory fee for access to your data, Ultrahuman Ring AIR is the clearest candidate. It is built for sleep, recovery, temperature, HRV and gentle nudges, but before buying you should separately check data export, regional features and the maturity of the integrations you need.

Comparison in one table

Device — Best use case — Subscription and cost of ownership — Battery — Main compromise

Oura Ring — Sleep, HRV, readiness, stress, women’s health — Membership: $5.99/month or $69.99/year for U.S. members; prices vary by region — Usually 5-8 days on Oura Ring 4 — The best insights are tied to membership

WHOOP — Recovery + strain + habits + screenless training — U.S. plans in the research set are listed from $199, $239 and $359/year for WHOOP One, Peak and Life; device is included in membership — 14+ days on WHOOP 5.0/MG — Without membership there is effectively no product; no screen or classic smartwatch features

Garmin — Sport, GPS, training readiness, HRV Status, Body Battery — Hardware is purchased separately; core wellness and sport metrics do not require an Oura/WHOOP-style wellness subscription — Strongly model-dependent; Venu 4 is rated up to 12 days in smartwatch mode — Watches can be less comfortable for sleep than a ring or strap

Ultrahuman — Ring for sleep and recovery without mandatory subscription — Ring AIR is listed from $349; access to ring data has no recurring subscription fee — 4-6 days — Less public clarity on API/export and less sport depth than Garmin or WHOOP

Sleep and HRV: where rings are stronger, and watches are not always worse

For night tracking, a ring usually wins in everyday life: it is lighter, has no glowing screen, does not catch on sleeves and is easier to forget. That makes Oura and Ultrahuman natural candidates if your main goal is to understand sleep, HRV, night heart rate, temperature and recovery.

Oura Ring 4 measures night heart rate, HRV, breathing, SpO2, temperature and movement. Active membership unlocks detailed sleep analysis, Readiness, Daytime Stress, Resilience, Cardiovascular Age, VO2 Max estimate, reports and Oura Labs. One important detail: Oura Labs is experimental. For example, the Blood Pressure Profile Study is available only in English for U.S.-based members, does not provide blood pressure measurements and is not a diagnostic feature.

Ultrahuman Ring AIR plays in a similar category, but its pitch is different: no required subscription. The product page lists Sleep Score, sleep stages, Dynamic Recovery, skin temperature, continuous HRV monitoring, stress rhythm and caffeine window. For someone who wants a ring and data without a monthly bill, that is a strong argument. But if you are building your own quantified-self pipeline, check how you will actually get data out of Ultrahuman before you buy. In open official material, it is easier to find the promise of data access without subscription than a complete public export or API document.

WHOOP is also strong for sleep, but its logic is different. It is less a night-only ring and more a continuous recovery coach. Sleep, Recovery and Strain are connected with training, the habit journal, stress and an AI layer. That is useful if you are willing to tell the system what you drank, how you trained, whether you traveled, got sick or took supplements.

Garmin should not be dismissed. HRV Status is built from overnight readings and needs roughly three weeks of regular sleep wearing the watch to establish a personal baseline. Body Battery uses HRV, stress and activity to estimate your energy reserve through the day. If you already wear Garmin around the clock, a separate ring may be redundant. If the watch bothers you at night, the data will have holes.

Sport and recovery: Garmin and WHOOP play a different game

Rings are comfortable for sleep, but sport is a harder environment. Barbells, kettlebells, pull-up bars, climbing, contact sports and even a tight bike grip expose the weakness of the form factor: the ring either gets in the way or you want to take it off. If you remove it for training, the recovery story after load becomes less connected.

Garmin is the most practical choice here. Even a wellness-oriented model like Venu 4 includes HRV Status, Body Battery, recovery time, training readiness, wrist-based running dynamics, women’s health tracking, Garmin Fitness Coach and up to 12 days of battery life in smartwatch mode. Dedicated sport lines such as Forerunner, fenix, epix, Instinct and Enduro go further: GPS, pace, power, routes, sensors, workouts, racing and long activities.

WHOOP is strong if you do not need a screen or wrist GPS, but you do want recovery discipline. Strain shows how heavy the day was, Recovery suggests whether to push or hold back, and the habit journal connects behavior to results. For strength work and team sports, a strap is easier to keep on than a ring. But for pace, maps, navigation and glanceable workout prompts, WHOOP does not replace Garmin.

Oura and Ultrahuman can work as a night layer next to sport watches. Example: Garmin for workouts, a ring for sleep. It costs more, but it removes the conflict between the best form factor for sport and the best form factor for sleep.

Stress, health and longevity: do not confuse guidance with diagnosis

All four products sell a similar promise: you can see HRV, sleep, heart rate, temperature and stress, then finally understand what is happening in your body. In practice, a wearable is useful less as a mini-doctor and more as a trend sensor. It can help you notice that alcohol, late meals, flights, illness or overreaching tank your recovery. It should not make medical decisions for you.

Oura is strong at soft interpretation: Readiness, Resilience, Daytime Stress, Cumulative Stress, Cardiovascular Age and Cardio Capacity make data easier to understand if you do not want to live in CSV files. WHOOP is moving toward a health platform: in 2026 the company announced on-demand clinician access in the U.S. for summer, EHR syncing, and new AI features called My Memory and Proactive Check-ins. That is interesting, but it is not the main reason to buy WHOOP outside the U.S. or if you do not want a wearable to hold more medical context.

Garmin uses a more athletic language: HRV Status, Body Battery, stress level, sleep, recovery time and training readiness. It feels less like a wellness journal and more like a dashboard for an active person. Ultrahuman focuses on nudges around sleep, recovery, temperature, stress, circadian rhythm and caffeine timing.

Regulated features need a separate warning. ECG, irregular rhythm notifications, blood pressure insights, AFib detection and similar functions almost always depend on country, model, user age, app version and regulatory status. WHOOP Life/MG, Garmin ECG App, Oura Labs and Ultrahuman PowerPlugs should not be compared as universal features for everyone. Before buying, check the exact country and exact model.

Women’s health: temperature helps, but it is not contraception by default

For cycle tracking, rings look stronger than watches because of night temperature and comfortable continuous wear. Oura offers Cycle Insights, Pregnancy Insights and integrations with apps such as Natural Cycles, Flo and Clue. That makes Oura the most mature option if you want temperature, sleep and women’s health in one app.

Garmin is also developing women’s health features: Venu 4 lists skin temperature for past ovulation estimates and improved period predictions. But Garmin explicitly says menstrual cycle tracking should not be used to support conception, contraception or birth control. That boundary matters: cycle predictions can help you observe patterns, but they are not a medical method.

WHOOP includes Women’s Hormonal Insights in its membership lineup. Ultrahuman lists temperature-based ovulation prediction. In both cases, the key questions are the same: availability in your country, clarity of the method, data export and how much you trust the app in a sensitive category.

Subscription, data and export: the hidden wearable cost

Buying a wearable is not only about the device price. After two years, the difference between buy it and wear it and pay to keep the insights becomes hard to ignore.

Oura: U.S. membership costs $5.99/month or $69.99/year. Over two years, that is about $140 with annual billing, on top of the ring price. Oura has an API V2, but for Gen3 and Ring 4 users, API access requires active Oura Membership. Data files can still be downloaded through Membership Hub, at least through a GDPR-compliant request path.

WHOOP: the model is fully subscription-based. In the U.S. storefront from the research set, WHOOP One, Peak and Life are listed from $199, $239 and $359/year, and the device is included in membership. WHOOP supports CSV data export and has a developer API, but continuous heart rate data is not available through the API. For WHOOP MG, some health data may be subject to separate retention rules.

Garmin: strongest for sport export. Garmin Connect can export activities in formats such as GPX, TCX, original/FIT and CSV, and users can request all-account data export through Garmin’s account tools. If you move workouts into Strava, TrainingPeaks, GoldenCheetah or your own spreadsheets, this may matter more than a beautiful sleep score.

Ultrahuman: the main advantage is no recurring subscription fee for Ring AIR data. The main question is data openness. If the app is enough for you, that may be fine. If you want to routinely extract raw or semi-structured data, do not buy blind: first check current export settings, API access and integrations.

Who Oura Ring is for

Oura is worth choosing if you want the most polished smart ring for sleep, recovery, HRV, readiness, stress and women’s health. It fits people who do not want to sleep with a sport watch, value clear reports and are comfortable paying for the app.

It is not the best fit if you are strongly against subscriptions, train heavily with barbells or want one device for GPS, pace, maps and workout screens. Oura is not a sport watch. It is a ring for sleep, recovery and long-term trends.

Who WHOOP is for

WHOOP fits people who think in systems: load, recovery, sleep, habits, stress, journal, coaching. It is especially logical if you train 3-6 times a week, do not want a screen on your wrist and are comfortable with annual billing.

It does not fit people who want to buy a device once, see notifications, use maps, play music, get quick workout screens or avoid a subscription model. WHOOP without membership is not a standalone gadget.

Who Garmin is for

Garmin is the choice for sport, data and autonomy. If you run, cycle, hike, prepare for races or want to connect sleep with training readiness, Garmin will usually give you more practical value for the money.

It is not ideal if you cannot sleep comfortably with a watch or want the most invisible tracker possible. Large sport models can be excellent by day and annoying at night. This is one of those cases where trying the device matters more than reading the spec sheet.

Who Ultrahuman Ring AIR is for

Ultrahuman Ring AIR is worth considering if you want a smart ring for sleep, recovery and temperature without a required monthly fee. It is especially interesting if you do not want HRV to become another subscription.

It is not the best choice if mature integrations, transparent API access, Garmin-level sport analytics or medical features with clear regional availability are critical to you. The potential is high, but check your exact use cases before buying.

Bottom line: choose the habit, not the metric

If you want one short answer: for sleep and soft longevity tracking, choose Oura if the subscription does not bother you. For training-led recovery, choose Garmin. For screenless recovery coaching, choose WHOOP. For a ring without a mandatory subscription, choose Ultrahuman.

But the best wearable is the one you do not take off. HRV, sleep score and readiness become useful only after weeks and months of continuous data. The final test is simple: can you sleep with it, charge it without irritation, pay for it without regret and change your behavior based on its prompts? If not, even the most accurate sensor becomes an expensive accessory.

Epigenetic clocks used to answer a dramatic but blunt question: how old does your body look compared with your birth certificate? The newer question is more useful: how fast are you aging now, and did your last intervention actually move the needle?

That shift is why third-generation epigenetic clocks matter. Tools such as DunedinPACE are designed less like a lifetime damage score and more like a speedometer. They do not replace blood work, imaging, fitness testing, or clinical judgment. But used carefully, they can add a missing layer to a longevity plan: whether your biology is trending in the right direction after changes in sleep, training, nutrition, weight loss, inflammation control, or medication.

The three generations of epigenetic clocks

DNA methylation is one way cells regulate gene activity. Across life, methylation patterns change in predictable ways. Epigenetic clocks use those patterns to estimate aging-related signals from a blood, saliva, or tissue sample.

First generation: chronological age predictors

The first major clocks, including early Horvath- and Hannum-style models, were built to predict chronological age from methylation. They were scientifically important because they showed that methylation carries a strong age signal across tissues.

Their weakness is practical: if a model is trained mainly to guess your calendar age, it may not be the best tool for deciding whether your health trajectory is improving. A 45-year-old with excellent cardiometabolic health and a 45-year-old with rising inflammation may both score close to 45.

Second generation: risk-linked biological age

Second-generation clocks moved closer to health outcomes. PhenoAge and GrimAge are commonly cited examples. They were designed around mortality risk, clinical chemistry, smoking-related methylation signatures, and other health-relevant endpoints rather than calendar age alone.

This made them more useful for risk stratification. If your GrimAge acceleration is high, that is more concerning than simply being methylation-estimated as older than your passport. But these clocks still often behave like accumulated-risk snapshots. They can be powerful, yet they may not be ideal for short feedback loops.

Third generation: pace of aging

Third-generation clocks try to estimate the rate of biological aging. DunedinPACE is the best-known commercial-facing example. It was developed from longitudinal data in the Dunedin Study, where researchers tracked changes across multiple organ-system biomarkers over time and then trained a methylation measure to estimate that pace.

In plain English: instead of asking “how old do you look?”, it asks “how much biological change are you accumulating per year?” A DunedinPACE value around 1.0 is often interpreted as roughly one biological year of change per chronological year. A higher value suggests faster pace; a lower value suggests slower pace. Exact interpretation depends on the lab, sample type, report version, and reference population.

Why rate-of-aging is more actionable

Longevity interventions are usually iterative. You change something, wait, measure, and adjust. A rate-of-aging marker fits that loop better than a static age estimate.

If you start resistance training, improve protein intake, reduce visceral fat, treat sleep apnea, or lower chronic inflammation, you do not want to wait decades to see whether the decision mattered. You want early directional evidence.

That does not mean DunedinPACE can validate every supplement stack or biohacking protocol. It means it may be useful as one layer in a measurement system, especially when paired with standard markers: ApoB, blood pressure, HbA1c, fasting insulin, hs-CRP, liver enzymes, kidney function, VO2 max, grip strength, waist-to-height ratio, sleep metrics, and medication history.

What a commercial test can actually tell you

A serious methylation report can be useful in four ways.

First, it gives you a baseline. If you have never measured biological aging, a first test is less a verdict than a starting line.

Second, it can track direction after interventions. Repeating the same test under similar conditions is more informative than comparing one-off results across different vendors.

Third, some reports bundle adjacent signals: estimated smoking exposure, inflammation-related methylation, immune-cell composition, organ-system aging, or disease-risk scores. These can generate better questions for your clinician, though they are not diagnoses.

Fourth, it can reveal mismatch. If your traditional labs look good but your pace-of-aging score is unexpectedly high, the next move is not panic. It is a structured audit: sleep, alcohol, overtraining, inflammation, medications, recent illness, weight change, and lab variability.

How to choose a biological age test

The market is noisy. A good test is not the one with the most dramatic dashboard. It is the one that gives you a validated measure, transparent sample handling, and a report you can act on without pretending it is a medical diagnosis.

1. Check which clock is included

Look for the exact algorithm name. “Biological age” is not enough. For this use case, the key phrase is DunedinPACE or another explicitly rate-of-aging measure. A test that only reports methylation age may still be interesting, but it is less suited to short-cycle intervention tracking.

TruDiagnostic lists TruAge with DunedinPACE, OMICmAge, organ-system age scores, telomere-related reporting, smoking and alcohol impact scores, and other methylation-derived outputs. Its positioning is strongly aligned with longitudinal self-tracking.

Elysium Health has offered Index, a biological age product based on DNA methylation. Before buying, verify the current report contents because product packaging, included algorithms, and availability can change.

2. Prefer repeatability over novelty

The best test is usually the one you can repeat consistently. Use the same vendor, same sample type, similar time of day, and similar health context. Do not compare a saliva-based result from one company with a blood-based result from another as if they were interchangeable.

3. Look for laboratory quality and privacy terms

For U.S. buyers, CLIA certification and HIPAA language are relevant signals, but they are not a full privacy audit. Read the consent form: data retention, research use, de-identification, deletion rights, third-party sharing, and whether raw methylation data can be downloaded.

4. Avoid tests that overpromise therapy selection

A methylation clock can support health decisions. It should not be the sole basis for prescription drugs, hormone therapy, aggressive fasting, senolytics, rapamycin, metformin, peptides, or other geroprotective experiments. If a vendor frames a clock as a standalone treatment engine, be skeptical.

A practical interpretation algorithm

Use the result as a feedback tool, not a personality test.

Step 1: Establish baseline context

Before sampling, record the previous 30 to 60 days: illness, vaccines, antibiotics, major stress, weight loss, alcohol intake, sleep debt, travel, training load, injuries, medication changes, and supplement changes. A methylation score without context is easy to overread.

Step 2: Pair the clock with standard biomarkers

A high pace-of-aging score becomes more meaningful if it aligns with elevated blood pressure, ApoB, insulin resistance, inflammation, poor sleep, low fitness, or low strength. If it does not align, repeat before making expensive decisions.

Useful companion platforms include InsideTracker for blood-marker-driven recommendations and Function Health for broad lab panels. They are not substitutes for an epigenetic clock, but they can explain why a clock may be moving.

Step 3: Change one major variable at a time

If you overhaul training, diet, sleep, supplements, and medication in the same month, you may improve your health but lose interpretability. For self-experimentation, make the biggest known-risk change first: sleep apnea treatment, alcohol reduction, blood pressure control, resistance training, protein adequacy, fiber intake, visceral-fat reduction, or smoking cessation.

Step 4: Retest on a realistic interval

For lifestyle interventions, retesting too soon creates noise. A three- to six-month interval is more defensible for most people than monthly testing. Clinical trials may use different schedules, but personal health decisions need enough time for behavior and biology to stabilize.

Step 5: Act on convergence, not one number

If DunedinPACE improves, hs-CRP drops, waist circumference shrinks, sleep improves, and strength rises, the signal is stronger. If the clock worsens while everything else improves, repeat the test and review confounders before changing course.

How to use the data for diet, training, and geroprotectors

Diet

Do not use methylation results to chase exotic diets first. Start with the interventions that already map to cardiometabolic and inflammatory risk: adequate protein, high-fiber plants, minimally processed foods, stable energy balance, lower alcohol exposure, and correction of deficiencies. If a test suggests faster aging and your blood work shows insulin resistance or inflammation, the diet target is clearer.

Training

A pace-of-aging result is most useful when combined with functional measures. Track VO2 max or a field proxy, grip strength, resting heart rate trend, blood pressure, and recovery. If your score is poor and your fitness markers are weak, the first prescription is probably not a niche compound. It is progressive aerobic work, resistance training, and recovery hygiene.

Supplements and geroprotectors

This is where restraint matters. NAD+ precursors, creatine, omega-3s, vitamin D correction, glycine, taurine, metformin, rapamycin, senolytics, and GLP-1-related weight-loss strategies all live in very different evidence categories and risk profiles. A methylation clock cannot tell you that you “need” rapamycin or that a supplement is working in isolation.

Use clocks to monitor broad trajectory after a physician-reviewed intervention plan. For prescription or experimental geroprotectors, the decision should sit on clinical indication, risk, contraindications, drug interactions, and medical supervision.

Who should consider testing

A methylation pace-of-aging test makes sense if you are already willing to act on basic health data and repeat the measurement. It is especially useful for people running a structured longevity program, recovering from a period of poor health, evaluating major lifestyle changes, or participating in clinician-guided preventive care.

It is less useful if you want a single number to rank yourself, if the result will trigger anxiety, if you are not prepared to repeat the test, or if you plan to use it to justify high-risk interventions without medical oversight.

The bottom line

Third-generation epigenetic clocks are not fortune tellers. Their value is narrower and more practical: they can help turn longevity from a vague aspiration into a measured feedback loop.

The right workflow is simple: choose a test that clearly reports a rate-of-aging measure, establish context, pair it with conventional biomarkers, change the highest-impact variables first, and retest with discipline. If the methylome, blood work, fitness, and lived experience all move in the same direction, you have something more useful than a biological age score. You have evidence that your system is responding.

Longevity is often sold as a promise to reach 120. Aging researchers talk about something else: lifespan, the total years lived, matters less than healthspan, the period when a person is independent, mobile and not dependent on treating chronic disease. The gap is easy to see. Someone can live to 85 and spend the last fifteen years with heart failure or dementia.

The concept itself is not new. What is new is the attempt to turn healthspan into something measurable. That is what this section of FUTURMAG is about: not “sleep more” advice, but technologies that make healthy aging testable.

Why measurement is the real problem

Healthspan has no single definition. Some define it as time before the first serious chronic disease, others as time before loss of independence, others through quality-of-life scales. That makes studies hard to compare and interventions hard to evaluate.

There is also a regulatory side. Regulators, including the FDA, do not recognize aging as an indication: a drug has to be approved for a specific disease. Trials of geroprotective drugs therefore rely on proxies such as diabetes, cardiovascular events or functional tests. The TAME trial of metformin was conceived to test that approach itself, to see whether a cluster of age-related diseases can work as an endpoint. Check its current status on the project’s official pages rather than in headlines.

Four tiers of tools

It helps to sort what the market offers by maturity.

1. Validated risk markers. Blood pressure, ApoB or non-HDL cholesterol, HbA1c, waist circumference, coronary artery calcium score. This layer is dull but the most reliable: decades of data link these numbers to outcomes.

2. Functional tests. Grip strength, walking speed, repeated chair stands, maximal oxygen uptake (VO₂max). They predict risk and independence well and cost almost nothing. We cover how watches digitize one of them in the VO₂max article .

3. Wearables. Rings and watches provide continuous data: resting heart rate, heart rate variability, sleep, activity. They are good for tracking one person’s trend and poor at absolute values; see the comparison of rings, straps and watches .

4. Omics and “aging clocks”. Epigenetic clocks, proteomic panels, metabolomics. This is the most exciting and most contested tier: the tools measure statistical patterns, not diagnoses. How to read such results is explained in our piece on third-generation epigenetic clocks .

What about interventions

In animal experiments several compounds extend lifespan; the best evidence is for rapamycin in the US National Institute on Aging’s Interventions Testing Program. In humans the picture is more modest: safety and effects on individual markers are being studied, but extension of healthy life has not been shown. More in our piece on supplements and senolytics .

The practical takeaway is that lifestyle changes remain the intervention with the strongest evidence, while technology helps you see where you stand and whether your chosen path is working.

How we rate technologies in the Human section

For every topic we state the stage: lab research, human trials, clinical use or consumer product. We separate “associated with risk” from “reduces risk”. We do not promise that a test or supplement will extend life, and we flag when a decision belongs with a doctor.

In 2018 JAMA Network Open published a Cleveland Clinic study that followed 122,007 patients who had undergone treadmill testing and compared their survival (Mandsager et al.). People with low cardiorespiratory fitness died more often than the rest, and the best, “elite” group lived longest. The authors found no upper limit beyond which the benefit disappears. The study is observational, so it cannot prove causation, but the association is so strong that VO₂max came to be seen as a key health measure.

What VO₂max is and how it is measured

VO₂max is the maximum amount of oxygen the body can use per minute per kilogram of body weight. Lab measurement requires a mask, a treadmill or cycle ergometer, and effort to exhaustion. It is accurate but expensive, unpleasant and rarely repeated.

How watches estimate it

Watches and bands do not measure gas exchange. They estimate VO₂max from the relationship between heart rate and speed (or power) during running or brisk walking, plus age, weight and sex. Garmin, Apple Watch, Polar and others display the number automatically. For people who train regularly and give the device enough outdoor data, estimates usually correlate with lab results, but notable scatter remains; watches often underestimate very fit athletes and err for people who rarely run.

So the rule is: compare yourself with yourself. A rise in the estimate over several months using the same method is an informative signal. An argument about “I have 48, my friend has 52” is not.

What matters for interpretation

• Results depend on conditions: heat, fatigue, hills and poor GPS can shift the number.
• Watches work better if heart rate is measured accurately; a chest strap is more reliable than optical sensors.
• Test in similar conditions: same route and time of day.
• If the number drops, do not panic. Compare with sleep, illness and training load over recent weeks.

How to improve it

The foundation is plenty of easy aerobic work (you can hold a conversation), plus one or two interval sessions a week, for example 4 × 4 minutes at a hard but controlled pace. These schemes are the best studied, but they do not suit everyone: people with heart disease and those who have not trained for a long time should talk to a doctor first.

When you need a real test

A lab test makes sense if you train endurance seriously, want precise training zones, or have questions about heart and lungs. For everyone else a watch gives enough information to see the trend.

How VO₂max fits into healthy aging overall is in our piece on healthspan .

Nearly every smartwatch and ring today shows a “stress level” or “readiness”. The basis is heart rate variability (HRV): tiny fluctuations in the intervals between heartbeats. The higher it is, the better, on average, the adaptability of the autonomic nervous system. But there are many assumptions between that fact and the everyday conclusion “you are stressed”.

What HRV measures

HRV reflects the balance of the sympathetic and parasympathetic systems, but it is also affected by sleep, alcohol, illness, exertion, breathing, age, temperature and time of day. Optical wrist sensors read pulse with light (photoplethysmography), and accuracy drops with movement. That is why almost all devices compute HRV at night, when you are still.

In practice this means:

• absolute numbers differ between people and devices, so comparing them is pointless;
• personal trend (your own average over 2-4 weeks) is informative: a marked drop with insomnia, illness or overtraining genuinely signals overload;
• a single “red” day is noise, not a diagnosis.

What technology does besides measuring

Biofeedback, training breathing with HRV feedback, has evidence of small-to-moderate benefit for anxiety and for lowering blood pressure, but the effect depends on regular practice, not on the device. Slow breathing at roughly six cycles per minute underlies most protocols.

There are also clinical digital methods. Regulators have already cleared some software products as treatment: the FDA, for example, has authorized cognitive behavioral therapy programs for insomnia and an adjunct app for major depressive disorder alongside antidepressants. These are not “relaxation apps” but products that went through clinical trials, and they are dispensed on indication and prescription.

What the data say about relationships

At the other end of the scale is the longest-running data source: the Harvard Study of Adult Development, which has followed participants since 1938. The main conclusion of its directors is that the quality of close relationships in midlife predicted health and well-being in old age better than cholesterol levels. These are observational data and do not prove causation, but they agree with many studies on loneliness and health risk.

The practical takeaway: a gadget can show that you are overloaded, but the solution is more often sleep, workload, a conversation with people close to you or professional help than a new sensor.

How to use devices without fooling yourself

1. Look at trends over weeks, not morning scores.
2. Cross-check against a log of sleep, caffeine and training to find the cause.
3. If a device treats anxiety with numbers rather than sensations, set it aside for a couple of weeks.
4. With persistent anxiety, insomnia or depression, see a doctor; wearable data can be brought to the appointment as a supplement.

For which devices measure sleep and recovery best, see our comparison of rings, straps and watches .

Muscle was long seen as a matter of appearance. Increasingly it is treated as an organ that determines metabolism, resilience to injury and independence in old age. And there is now a technological reason to say it louder: a new generation of weight-loss drugs has made doctors ask what exactly a person loses along with the weight.

Strength as a biomarker

A grip dynamometer is cheap, and the result predicts outcomes well. In the large PURE study across 17 countries (Leong et al., Lancet, 2015), weaker grip was linked to higher risk of death from all causes and from cardiovascular disease, and the association held after adjusting for age and other factors. That does not mean weak grip causes disease: it reflects overall condition. But as a cheap screening test it is useful.

With age, muscle mass and strength decline, which is called sarcopenia. The rate depends on activity and nutrition, and resistance training remains the most reliable way to slow it.

Why GLP-1 changed the conversation

Semaglutide and tirzepatide help many people lose a substantial share of their weight. But in clinical trials a notable share of the lost mass is not fat: estimates usually say roughly a quarter to a third, though exact figures depend on the drug, dose and measurement method. For a young person that is tolerable; for an older person with low baseline muscle it risks losing function along with weight.

Practical conclusions discussed in clinical guidance:

• combine therapy with resistance training;
• watch protein intake (individually, with a doctor);
• track not only weight but body composition and function (strength, walking speed).

Meanwhile pharma companies are testing drugs meant to protect or build muscle during weight loss, such as myostatin and activin blockers. These are early- to mid-stage trials: none can yet be called a proven substitute for training.

What to measure and with what

• Grip dynamometer: the most accessible test; compare with age norms.
• Five chair stands: leg strength with no equipment.
• Bioimpedance scales: handy for trends, but readings depend on hydration and the model; do not trust absolute numbers.
• DEXA: a more accurate body-composition method, suitable for periodic checks on a doctor’s advice.
• Smartwatches: estimate load indirectly; limited for strength work specifically.

A minimum program

For most adults, guidelines converge on two strength sessions a week covering the major muscle groups with gradually increasing load. What matters is progression: if weight and repetitions do not rise, the muscles have nothing to adapt to. People with heart or joint disease, osteoporosis, or those taking weight-loss drugs should consult a doctor first.

For links to nutrition and glucose sensors see our pieces on personalized nutrition and CGM .

If nutrition depended only on general rules, dietitians would have an easy job. In practice the same foods affect people differently, and an industry has grown around that: apps that track glucose, microbiome tests, DNA kits, AI assistants that analyze a photo of your plate. What of this is supported, and what is just nicely packaged?

What the science shows

The best-known study is PREDICT, run by King’s College London and other centers. It showed that responses to identical food vary a lot between people: glucose and lipids after a meal depended not only on the meal’s composition but also on sleep, time of day, physical activity and the microbiome, while genetics explained only a small share of the differences (Berry et al., Nature Medicine, 2020). The idea that one size fits all really is weak.

It does not follow that a personal algorithm always beats a simple rule. Studies where people received personalized glucose-based advice showed modest improvement in some participants, and large head-to-head comparisons with good baseline advice are scarce.

What actually scales

Fiber. High fiber intake is consistently linked in large reviews to lower risk of cardiovascular disease and type 2 diabetes. Most people worldwide eat less than the recommended 25-30 g a day.

Protein. Older adults and people who lift need more than young sedentary people: a range of 1.0-1.2 g per kg of body weight and above is often cited, but your individual target should come from a doctor, especially if you have kidney disease. More on the link to muscle in our piece on strength training .

Ultra-processed food. In a controlled NIH study by Kevin Hall (2019), participants on an ultra-processed diet ate roughly 500 kcal a day more than on a minimally processed one and gained weight. That does not make all such food harmful, but it points to a mechanism of overeating.

Where technology really helps

• Food recognition from photos. AI identifies a dish well but gets portions and composition wrong. Good for building a logging habit, not for precise counting.
• CGM for a limited time. Helps you see your own responses; see the piece on glucose sensors .
• Microbiome analysis. The market is ahead of science: there are no firm dietary recommendations from standard tests yet, and results depend on the lab and method.
• Genetic nutrition tests. Justified for rare conditions (lactose intolerance, celiac disease), not for “choosing the perfect diet”.

A practical minimum

1. Fiber first (vegetables, legumes, whole grains) and enough protein, then everything else.
2. If you are interested in personalization, choose a service that explains its method and publishes research, not one that only shows attractive scores.
3. Judge results not by weekly weight but by markers over several months: blood pressure, HbA1c, lipids, how you feel.

Not long ago continuous glucose monitoring (CGM) was a tool for people with diabetes. In 2024 over-the-counter versions appeared in the US: Dexcom Stelo and Abbott Lingo are sold to people who want to track glucose without a diagnosis. A coin-sized sensor sticks to the arm and sends a value to an app every few minutes. The question is what a healthy person should do with that curve.

What the sensor actually measures

A CGM reads glucose in interstitial fluid, not blood, so readings lag lab values by minutes and can differ noticeably. It does not replace a blood test and cannot diagnose. What it shows is what a single fasting test cannot: how fast glucose rises after a meal, how long it stays up, and what happens overnight.

Why it is interesting

Responses to the same food vary widely. In the PREDICT study of about a thousand people, individual glucose responses to identical test meals differed markedly, even between twins (Berry et al., Nature Medicine, 2020). That helps explain why “universal” diets do not work for everyone, and it is the basis for commercial personalized-nutrition apps.

In practice a sensor can show:

• which of your regular meals cause sharp spikes in you specifically;
• the effect of meal order, a walk after lunch, poor sleep;
• unusual overnight spikes and dips worth discussing with a doctor.

Where usefulness ends

For healthy people there are no convincing trials showing that watching the glucose curve improves outcomes such as cardiovascular events, diabetes or lifespan. Short post-meal swings are normal: a peak is not a disease. The danger is that people start fearing normal things and restricting healthy food because of a red arrow.

Rely on solid markers: HbA1c, fasting glucose, waist circumference, blood pressure, lipids. CGM is an add-on that makes sense for a short period (two to four weeks) to learn your responses, not something to wear permanently.

What GLP-1 drugs change

GLP-1 receptor agonists (semaglutide, tirzepatide) have become the main tool for treating obesity and type 2 diabetes in recent years and have shown fewer cardiovascular events in large trials in specific groups. They change the very meaning of metabolic control: many patients reach normal numbers without strict diets. But these are drugs with side effects and indications, chosen by a doctor. Why muscle mass matters more alongside them is covered in our piece on strength training .

How to use the technology sensibly

1. If you have risk factors (family history of diabetes, excess weight, prediabetes), get an HbA1c first and discuss the result with a doctor.
2. Wear the sensor for a limited time with a concrete question, for example how you react to breakfast.
3. Do not compare your numbers with screenshots from social media.
4. Change one thing at a time and repeat the measurement.

Rapamycin, the dasatinib and quercetin combination, and NAD+ precursors are the three names that come up most in talk about “anti-aging pills”. All three have real science behind them, and in all three cases the science is more modest than the retellings suggest. Let us go stage by stage to see where the data ends.

How to read “extended lifespan”

Most of the strong results come from laboratory mice. The best test bed is the National Institute on Aging’s Interventions Testing Program (ITP): experiments run in parallel at several sites on genetically diverse animals, which reduces the chance of one-off results. In it, rapamycin extended mouse lifespan in both males and females.

Even so, it does not mean humans get the same effect. Mice have a different lifespan, metabolism and causes of death. Everything below should be read as “the hypothesis is being tested”, not “the compound works”.

Rapamycin (sirolimus)

Rapamycin blocks the mTOR signalling pathway, which links a cell’s nutrient supply to growth. It has long been used as an immunosuppressant after transplants, so its high-dose safety profile is well known: mouth ulcers, changes in lipids and glucose, and a higher risk of infection among the side effects.

For a healthy person the question is low, intermittent dosing. There are small safety and biomarker studies, but no large trials asking whether people stay healthy longer. Any off-label use is a decision for a physician, not an experiment from an internet protocol.

Senolytics

The idea: with age, “senescent” cells that have stopped dividing accumulate and release pro-inflammatory signals. If they are removed selectively, tissue might work better. In mice, clearing such cells improved several measures.

In people the data is early: small pilot studies of dasatinib plus quercetin in conditions where senescent cells are suspected to play a role, such as diabetic kidney disease and pulmonary fibrosis. These are safety and mechanism studies, not proof of benefit for a healthy person. Dasatinib is a cancer drug with serious side effects and does not exist as a supplement.

NAD+ precursors (NMN, nicotinamide riboside)

Levels of NAD+, a molecule involved in cellular energy metabolism, decline in tissues with age. In human studies, precursor supplements do raise NAD+ in blood. The open question is whether that changes muscle, vascular or metabolic function. Results so far are mixed and mostly come from small, short trials.

Product quality also needs checking. The supplement market is poorly standardized, and the legal status of NMN differs by country and has changed over time, so check the current rules with your national regulator.

What follows from this

• Mouse data is a reason for trials, not for self-treatment.
• If someone offers a rapamycin or senolytic “protocol” outside a clinic, ask about the indication, monitoring and who is responsible.
• The only interventions with demonstrated effects on healthy life are physical activity, blood pressure and lipid control, not smoking and sleep. How to measure the result is a separate question, and there technology already helps.

Not long ago, confirming Alzheimer’s disease during life took expensive PET imaging or a lumbar puncture. In recent years the picture has changed quickly: blood tests for specific proteins have appeared, along with drugs that slow the disease at an early stage. This is a technological shift that is important to understand and not to overrate.

What changed in diagnosis

The key new marker is phosphorylated tau, p-tau217, in plasma. In studies it correlates well with amyloid plaques in the brain on PET. In 2025 the FDA for the first time cleared for clinical use a plasma test based on the p-tau217 to amyloid-beta 42 ratio (Lumipulse) to help diagnose adults with symptoms. Note the wording: it is about confirming a diagnosis in a person with complaints, not mass screening of healthy people.

Reasons for caution: a positive result does not guarantee symptoms will appear or when; in some people the marker rises with kidney disease; and information about future risk without a means of intervention can do psychological harm.

What changed in treatment

Lecanemab (Leqembi) and donanemab (Kisunla), antibodies against amyloid, have been approved in the US and slowed cognitive decline in trials in people with early-stage disease. The effect is moderate, and treatment requires regular infusions and MRI monitoring because of the risk of brain swelling and microbleeds (ARIA). It is not a cure for dementia, but it is the first time drugs act on the biology of the disease. Availability and cost differ between countries.

What can be done now

The Lancet Commission on dementia, in its 2024 update, identified 14 modifiable risk factors and estimated that about 45% of dementia cases could in principle be prevented or delayed. The list: hypertension, hearing loss, high LDL cholesterol, smoking, diabetes, physical inactivity, obesity, excessive alcohol use, head injury, air pollution, social isolation, vision loss, depression and less education.

The 45% estimate is modelled, not a promise: it is the share that could be removed if the factors disappeared across the whole population. But the practical implications are clear: control blood pressure, check hearing and vision, stay active, do not smoke, keep up social contact. Hearing aids and hypertension treatment are among the best-supported measures.

What about “brain training” and supplements

Cognitive training apps improve performance on the trained tasks, but transfer to everyday memory and protection against dementia is weakly supported. Large supplements such as omega-3 and vitamins have not shown convincing prevention in people without deficiency. Multi-component lifestyle programs, such as the Finnish FINGER trial, gave a moderate benefit on cognitive tests but required a lot of effort and support.

What to do with this knowledge

1. Do not buy commercial “Alzheimer’s risk panels” without a doctor’s order.
2. If you notice persistent memory problems, early consultation gives more options than waiting.
3. For everyone else, “brain health” means blood pressure, sleep, hearing, physical activity and social life.

For how technology fits into the broader picture of healthy aging, see our piece on healthspan .

The classic checkup is blood pressure, a blood count, cholesterol and glucose. Next to it a separate industry of “deep diagnostics” has grown: extended lipid panels, whole-body MRI, blood tests for dozens of cancers from one tube, genetic reports. Some of this has genuinely improved prevention, and some is still more product than medicine. Let us separate them.

What to know first

ApoB and Lp(a). LDL cholesterol measures the cholesterol carried in particles, while ApoB counts the atherogenic particles themselves, so for some people it reflects risk better. Lipoprotein(a) is largely genetic and changes little over a lifetime; a European consensus statement recommends measuring it at least once in adults. These tests are inexpensive and can change a treatment decision.

HbA1c and blood pressure. Dull, but these catch prediabetes and hypertension early. A home cuff validated against a clinic reading gives more information than a single measurement a year.

Coronary artery calcium score. A non-contrast CT shows calcified plaque in the heart’s arteries. The result helps a doctor decide whether a person at intermediate risk should take a statin. It does not replace a discussion of risk factors and is not for everyone.

What is debated

Whole-body MRI in healthy people. The method finds many incidental findings, lesions that pose no threat but trigger further tests. Professional societies do not recommend it as screening for people without symptoms; benefit has been shown only in certain high-risk groups, such as hereditary syndromes.

Multi-cancer early detection (MCED) blood tests. Tests that read DNA shed by tumors into the blood are one of the most visible technology trends in oncology. But large randomized trials have not yet shown that such screening lowers mortality, and sensitivity for early stages is limited for some methods. Treat them as an addition to proven screening (colonoscopy, mammography, HPV testing), not a replacement.

Genetic reports on “aging risks”. Polygenic risk scores are advancing quickly, but their accuracy depends on ancestry, and the step from score to recommendation is often weaker than the report implies.

How to build a plan

1. Start with a physician and baseline labs, not with a service package.
2. For every test ask: what decision will change depending on the result?
3. Keep results in one place and compare trends rather than single numbers; wearables help here if you remember their limits.
4. From “biological clocks” choose what you can repeat yearly and compare with lifestyle changes; see our guide to epigenetic clocks .
5. If a finding is unexpected, do not be afraid to repeat the test and discuss the interpretation with a doctor.

A good checkup does not increase the number of tests. It lowers the chance of a surprise in ten years.